Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma

  • Acta Haematol. 2000;104(2-3):128-30. doi: 10.1159/000039746.
T Okamoto  1 ,  Y Nishimura ,  S Yamada ,  S Yamada ,  T Itoh ,  A Mori ,  K Saheki ,  M Okada ,  H Takatsuka ,  H Wada ,  A Tamura ,  Y Fujimori ,  E Kakishita
Affiliations
  • 1. Second Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan. [email protected]
PMID: 11154989 DOI: 10.1159/000039746
Abstract

It is known that the Topoisomerase II inhibitors, MST-16 (sobuzoxane) and VP-16 (etoposide), are effective for the treatment of lymphoma. Five patients with refractory or relapsed non-Hodgkin's lymphoma (NHL) were treated with a combination of oral MST-16 and VP-16 over a long period. Two patients had severely refractory NHL. The remaining 3 patients could not be treated with intensive chemotherapy because of severe organ dysfunction or a poor hematopoietic reserve. All 5 are alive and well after MST-16 and VP-16 treatment. MST-16 and VP-16 are effective for NHL when intensive chemotherapy is ineffective or contraindicated.

Products